Your browser doesn't support javascript.
loading
Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib.
Hughes, Timothy P; Lipton, Jeffrey H; Spector, Nelson; Cervantes, Francisco; Pasquini, Ricardo; Clementino, Nelma Cristina D; Dorlhiac Llacer, Pedro Enrique; Schwarer, Anthony P; Mahon, Francois-Xavier; Rea, Delphine; Branford, Susan; Purkayastha, Das; Collins, LaTonya; Szczudlo, Tomasz; Leber, Brian.
Afiliação
  • Hughes TP; South Australian Health and Medical Research Institute, Division of Haematology and Centre for Cancer Biology, South Australia Pathology, University of Adelaide, Adelaide, Australia;
  • Lipton JH; Princess Margaret Hospital, Leukemia Clinic, Blood and Marrow Transplant Centre, Apheresis Unit, Toronto, ON, Canada;
  • Spector N; Universidade Federal do Rio de Janeiro, Department of Clinical Medicine, Rio de Janeiro, Brazil;
  • Cervantes F; Hospital Clínic L'Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain;
  • Pasquini R; Universidade Federal do Paraná, Hospital de Clinicas, Curitiba, Paraná, Brazil;
  • Clementino NC; Hospital Das Clinicas da Universidade Federal de Minas Gerais, Belo Horizonte, Brazil;
  • Dorlhiac Llacer PE; Hospital das Clinicas, Faculdade de Medicina da Universidade de São Paulo, Hematology Department, São Paulo, Brazil;
  • Schwarer AP; Hematology Department, Alfred Hospital, Melbourne, Australia;
  • Mahon FX; Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Bordeaux and Laboratoire Hématopoïèse Leucémique et Cible Thérapeutique, Biothérapies des Maladies Génétiques et Cancers, Inserm U1035, Université Bordeaux Ségalen, Bordeaux, France;
  • Rea D; Service des Maladies du Sang et EA3518, Hôpital Saint-Louis, Paris, France;
  • Branford S; Centre for Cancer Biology, South Australia Pathology, University of Adelaide, Adelaide, Australia;
  • Purkayastha D; Novartis Pharmaceuticals Corporation, East Hanover, NJ; and.
  • Collins L; Novartis Pharmaceuticals Corporation, East Hanover, NJ; and.
  • Szczudlo T; Novartis Pharmaceuticals Corporation, East Hanover, NJ; and.
  • Leber B; McMaster University and Juravinski Hospital and Cancer Centre, Hamilton, ON, Canada.
Blood ; 124(5): 729-36, 2014 Jul 31.
Article em En | MEDLINE | ID: mdl-24948656
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperazinas / Pirimidinas / Benzamidas / Leucemia Mielogênica Crônica BCR-ABL Positiva / Proteínas de Fusão bcr-abl / Inibidores de Proteínas Quinases / Substituição de Medicamentos Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2014 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperazinas / Pirimidinas / Benzamidas / Leucemia Mielogênica Crônica BCR-ABL Positiva / Proteínas de Fusão bcr-abl / Inibidores de Proteínas Quinases / Substituição de Medicamentos Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2014 Tipo de documento: Article